Ironwood Pharmaceuticals Inc (IRWD) concluded trading on Thursday at a closing price of $0.70, with 4.03 million shares of worth about $2.82 million changed hands on the day. Half year performance of the stock remained negative as price took a plunge of -83.30% during that period and on May 08, 2025 the price saw a loss of about -11.63%. Currently the company’s common shares owned by public are about 161.81M shares, out of which, 156.66M shares are available for trading.
Stock saw a price change of -23.25% in past 5 days and over the past one month there was a price change of -36.95%. Year-to-date (YTD), IRWD shares are showing a performance of -84.20% which decreased to -91.37% when we look at its performance for past 12 months. Over the period of past 52 weeks, stock dropped to lowest price of $0.59 but also hit the highest price of $8.23 during that period. The average intraday trading volume for Ironwood Pharmaceuticals Inc shares is 3.28 million. The stock is currently trading -16.69% below its 20-day simple moving average (SMA20), while that difference is down -41.92% for SMA50 and it goes to -79.23% lower than SMA200.
Ironwood Pharmaceuticals Inc (NASDAQ: IRWD) currently have 161.81M outstanding shares and institutions hold larger chunk of about 86.08% of that.
The stock has a current market capitalization of $113.25M and its 3Y-monthly beta is at 0.37. It has posted earnings per share of -$0.20 in the same period. It has Quick Ratio of 4.69. Volatility of a stock is a metric used to know how much the price of that stock is under influence and for IRWD, volatility over the week remained 13.94% while standing at 14.49% over the month.
Analysts are in expectations that Ironwood Pharmaceuticals Inc (IRWD) stock would likely to be making an EPS of 0.04 in the current quarter, while forecast for next quarter EPS is 0.13 and it is 0.44 for next year. For the current quarter EPS, analysts have given the company a lowest target 0.04 which is 0.04 at the higher side of the target for the same. When we compare those targets with actual EPS, we find that company posted an EPS of 0.0 in the same quarter a year ago. Stock’s fiscal year EPS is expected to rise by 1644.75% while it is estimated to increase by 102.88% in next year. EPS is likely to grow at an annualized rate of 141.01% for next 5-years, compared to annual growth of -47.49% made by the stock over the past 5-years.
On April 14, 2025, Citizens JMP Downgrade their recommendations, while on September 09, 2024, Leerink Partners Initiated their ratings for the stock with a price target of $5. Stock get an Equal weight rating from CapitalOne on August 08, 2024.
